Rapport CEO Abraham Ceesay (L) and director Reid Huber
Janssen's neuro division churns out Rapport, a new $100M biotech from Third Rock’s clinical data hunt
A new neuroscience biotech is in the works, and it’s already in the clinic with an epilepsy drug born out of Johnson & Johnson’s Janssen …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
